Insights

Gathering insights about Genetics…

Similar companies to Genetics

Genetics Tech Stack

Genetics uses 8 technology products and services including Open Graph, Angular, iOS, and more. Explore Genetics's tech stack below.

Open Graph
Content Management System
Angular
Javascript Frameworks
iOS
Programming Languages
C#
Programming Languages
Yoast SEO
Search Engines
ZURB Foundation
UI Frameworks
Apache HTTP Server
Web Servers
FitVids.js
Web Tools And Plugins

Media & News

Opus Genetics to Participate in Upcoming Investment Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in the following investor conferences.
Nov 20, 2025 | www.globenewswire.com
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease community Initial data expected in Q1 2026 RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the first participant has been dosed in the Company's OPGx-BEST1 Phase 1/2 clinical trial for Best disease (BEST1).
Nov 13, 2025 | www.globenewswire.com
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.29 per share a year ago.
Nov 12, 2025 | www.zacks.com
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
- Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision - - Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 - - OPGx-BEST1 gene therapy program underway with recruitment ongoing in Phase 1/2 trial for the treatment of BEST1 disease - - Supplemental New Drug Application submission planned by year-end 2025 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia - - Strengthened capital position from recent equity offering and non-dilutive funding from patient advocacy groups - RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update.
Nov 12, 2025 | www.globenewswire.com
Opus Genetics Announces $23 Million Registered Direct Offering
- Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”) a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it has entered into a securities purchase agreement to sell securities in a registered direct offering (the “offering”) for gross proceeds of approximately $23 million, before deducting offering expenses.
Nov 06, 2025 | www.globenewswire.com
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5 First participant enrolled in run-in period for planned adaptive Phase 3 trial Company intends to apply for the FDA's new Rare Disease Evidence Principles (RDEP) review process OPGx-LCA5 has the potential to be the first gene therapy and one-time treatment for Leber congenital amaurosis (LCA) type 5 Recent $23 million financing led by Perceptive Advisors and Balyasny Asset Management to advance LCA5 and BEST1 programs and fund current operating plans into second half of 2027 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, today announced the successful completion of a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the U.S. Food and Drug Administration (FDA) regarding OPGx-LCA5, its gene therapy candidate for Leber congenital amaurosis (LCA) caused by mutations in the LCA5 gene.
Nov 06, 2025 | www.globenewswire.com
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's 2021 Inducement Plan, as amended, as a material inducement to employment to James Farrell, the Company's newly appointed Executive Director of Business Development, as well as to one non-executive employee, in each case, who were not previous employees or directors of the Company.
Nov 04, 2025 | www.globenewswire.com

Genetics's Email Address Formats

Genetics uses at least 1 format(s):

Genetics Email Formats	Example	Percentage
First.Last@genetics.nl	John.Doe@genetics.nl	58%
First@genetics.nl	John@genetics.nl	30%
F.Last@genetics.nl	J.Doe@genetics.nl	8%
FLast@genetics.nl	JDoe@genetics.nl	4%

Frequently Asked Questions

Where is Genetics's headquarters located?

Genetics's main headquarters is located at Bouwmeesterweg 8, 1333LC Almere, Flevoland 1333LC, NL. The company has employees across 6 continents, including EuropeAsiaNorth America.

What is Genetics's stock symbol?

Genetics is a publicly traded company; the company's stock symbol is IRD.

What is Genetics's official website and social media links?

Genetics's official website is genetics.nl and has social profiles on LinkedIn.

What is Genetics's NAICS code?

Genetics's NAICS code is 5112 - Software Publishers.

How many employees does Genetics have currently?

As of October 2025, Genetics has approximately 79 employees across 6 continents, including EuropeAsiaNorth America. Key team members include Cto, Sales Directeur, Senior Assessor, Senior Consultant, Architect, Ciso & Projectmanager: E. D.Product Owner: B. T.Customer Service Manager: P. O.. Explore Genetics's employee directory with LeadIQ.

What industry does Genetics belong to?

Genetics operates in the Software Development industry.

What technology does Genetics use?

Genetics's tech stack includes Open GraphAngulariOSC#Yoast SEOZURB FoundationApache HTTP ServerFitVids.js.

What is Genetics's email format?

Genetics's email format typically follows the pattern of First.Last@genetics.nl. Find more Genetics email formats with LeadIQ.

When was Genetics founded?

Genetics was founded in 1993.

Genetics

Q: What is Genetics's official website and social media links?

Genetics's official website is genetics.nl. Genetics has social profiles on LinkedIn.

Q: How many employees does Genetics have currently?

Genetics has approximately 79 employees.

Q: What technology does Genetics use?

Genetics's tech stack includes easy pie chart, Microsoft Azure, Swiper, .NET, Android.

Software DevelopmentNetherlands51-200 Employees

Genetics is kennisleverancier op het gebied van Milieu, Bouw, Bodem, Geluid, Water en Ruimtelijke Ordening en combineert ICT expertise met kennis van VTH processen en –vraagstukken. Sinds 1993 is een stevige marktpositie opgebouwd.

Onze opdrachtgevers zijn overheidsinstanties zoals regionale uitvoeringsdiensten (RUD), gemeentes, provincies, milieudiensten en waterschappen. Onze consultants hebben vakinhoudelijke kennis en ervaring op bouw-, milieu- en bodemterrein, opgedaan bij gemeentes en provincies.

Als totaalleverancier werkt Genetics nauw samen met VNG, KING en ICTU en partners.